Indication · Otolaryngology (ENT)
Thyroid nodules and thyroid disease
Last checked: Nov 19, 2026Source: FDA, ClinicalTrials.gov
Devices
135
Cleared or approved since 2000
PMA and De Novo
3
Higher-risk or first-of-kind devices
Breakthrough devices
2
Authorized through June 30, 2026
Recruiting device trials
13
127 device trials in all
Breakthrough-designated devices
- Koios DS (3.8)Koios Medical, Inc. · 2026
- Automated Aortic Stenosis Software (AutoAS)GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC · 2026
Devices
135 devices. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- Fluobeam 800 Clinic Imaging Device used with Fluocase 800 Control System
Fluoptics · De Novo · Parathyroid Autofluorescence Imaging Device · newest 2018
- Parathyroid Detection (Model PTeye) System
Aibiomed, Corp. · De Novo · Parathyroid Autofluorescence Detection Device · newest 2018
- QuantX
Quantitative Insights, Inc. · De Novo · Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer · newest 2017
57 more devices with a free account
Showing the first 60. Narrow by pathway, or open a device type below.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- NIRAF-Guided Parathyroid Identification During ThyroidectomyPivotal-lookingRecruiting
Ss. Cyril and Methodius University of SkopjeAcademic, hospital or other
NCT07617584 · 280 participants (planned) · Start Sep 1, 2026 · Primary completion Jun 1, 2029
Device: Wearable Near-Infrared Autofluorescence Imaging System · For: Hypocalcemia; Hypoparathyroidism; Thyroid Diseases and 3 more
Sites: Skopje, North Macedonia
- Comparing a New 3D Technology Used to Measure Thyroid Nodule Volume to Standard UltrasoundEnrolling by invitation
Sarasota Memorial Health Care SystemAcademic, hospital or other
NCT07178080 · 75 participants (planned) · Start Sep 8, 2025 · Primary completion Sep 8, 2027
Device: PIUR tUS Infinity Ultrasound · For: Thyroid Nodules; Thyroid Nodule
Sites: Sarasota, Florida
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07218315 · 15 participants (planned) · Start Feb 11, 2026 · Primary completion Jan 31, 2029
Device: CellFX nsPFA Percutaneous Electrode System · For: Thyroid Carcinoma
Sites: Sarasota, Florida; Houston, Texas
124 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- Radioimmunoassay, Thyroid-Stimulating Hormone (JLW)35
- System, Test, Thyroid Autoantibody (JZO)34
- Radioimmunoassay, Free Thyroxine (CEC)19
- Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer (POK)16
- Enzyme Immunoassay, Non-Radiolabeled, Total Thyroxine (KLI)8
- System, Test, Thyroglobulin (MSW)6
- Parathyroid Autofluorescence Imaging Device (QDG)5
- Radioimmunoassay, Calcitonin (JKR)4
- Thyroglobulin, Antigen, Antiserum, Control (DDC)3
- Immunochemical, Thyroglobulin Autoantibody (JNL)3
- Radioimmunoassay, Total Triiodothyronine (CDP)1
- Parathyroid Autofluorescence Detection Device (QDF)1
Research
- Device studies on thyroid nodule across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.